Bone Marrow Transplantation (2018) 53:347–351 https://doi.org/10.1038/s41409-017-0054-8 CORRESPONDENCE Effectiveness and tolerability of ﬁrst-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma 1 2 2 3 1 1 ● ● ● ● ● ● Umberto Falcone Haiyan Jiang Shaheena Bashir Richard Tsang Vishal Kukreti Armand Keating 1 1 Michael Crump John Kuruvilla Received: 26 May 2017 / Revised: 28 October 2017 / Accepted: 30 October 2017 / Published online: 21 December 2017 © Macmillan Publishers Limited, part of Springer Nature 2018 Mantle cell lymphoma (MCL) is an aggressive B-cell (TBI). Rituximab was approved as part of combination lymphoma accounting for 6–10% of non-Hodgkin lym- chemotherapy for MCL in Ontario in 2003, and RM was phoma, characterized by the chromosomal translocation t approved in 2006. Therefore, rituximab was incorporated (11;14)(q13;q32), de-regulated expression of cyclin D1 , into pre- and post-ASCT management at these time points. and median overall survival (OS) of 5–7 years . First-line Before 2006 patients received no maintenance, while after high-dose chemotherapy (HDT) followed by autologous this date, RM was offered to all patients unless contra- stem cell transplant (ASCT) has been reported to improve indicated. MCL diagnosis was conﬁrmed according to patient outcomes [3, 4].
Bone Marrow Transplantation – Springer Journals
Published: Dec 21, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera